Views & Analysis The power of crowdsourced R&D Drug R&D is still dogged by attrition, duplication and waste.
News Dismay but little surprise as NICE rejects Alzheimer's drugs Eli Lilly and Eisai's hopes of making their Alzheimer's disease therapies available to NHS patients in England have been knocked back once again.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
